Pharmaceutical industry news

Fresh and Healthy Revisited - Brownsville Herald

Fresh and Healthy Revisited Brownsville Herald, TX United States - 59 minutes ago We have learned that diet is closely related to cardiovascular disease, stroke, and diabetes. These three leading causes of death strike our families, ...

China Biotech Week in Review: Earnings, Deals and Drug Development - istockAnalyst.com

China Biotech Week in Review: Earnings, Deals and Drug Development istockAnalyst.com, OR - 1 hour ago Officials want a large supply of the vaccine for the victims of the recent earthquake, as they seek to stave off any outbreak of infectious disease in the ...

Don't bother with foods that lower cholesterol - Telegraph.co.uk

Don't bother with foods that lower cholesterol Telegraph.co.uk, United Kingdom - May 30, 2008 GPs should instead prescribe statins, which are proven to reduce the risk of cardiovascular disease, the document said. They lower the levels of bad ...

Before African languages become extinct - Daily Sun

Daily Sun

Before African languages become extinct Daily Sun, Nigeria - 36 minutes ago She is a graduate of College of Medicine, University of Ibadan (MBBS) with a Diploma in Tropical Medicine & Infectious Diseases and Masters in Public Health ...

Single pill for all lifestyle ailments - Times of India

Single pill for all lifestyle ailments Times of India, India - May 29, 2008 Cardiovascular diseases are the world's leading killer, accounting for over 17 million or 30% of total global deaths. In India, over 10 crore people are ...

Sun Pharma: Buy - Hindu Business Line

Hindu Business Line

Sun Pharma: Buy Hindu Business Line, India - 3 hours ago Investors with a 3-5 year perspective can buy the stock of Sun Pharmaceutical Industries (Sun), an integrated speciality pharmaceutical company that ...

Sun Pharma: Buy - Hindu Business Line

Hindu Business Line

Sun Pharma: Buy Hindu Business Line, India - 2 hours ago ... share in a highly fragmented market and enjoys a position of strength in brands catering to therapy areas of psychiatry (Repace), neurology (Oxetol), ...

Infinity Announces Clinical Data Confirming Activity and Safety of ... - FOXBusiness

Infinity Announces Clinical Data Confirming Activity and Safety of ... FOXBusiness - 1 hour ago Infinity is also developing an oral inhibitor of Hsp90, IPI-493, and expects to commence a Phase 1 clinical trial with IPI-493 in mid-2008. ... Infinity Drug Slows Spread of Deadly Stomach Cancera FDA Clears ... Xconomy Infinity to begin phase 3 trial of cancer drug Reuters Infinity, Astra Feel Need For Speed Forbes CNNMoney.com all 12 news articles

Little growth seen for publishers - Los Angeles Times

Little growth seen for publishers Los Angeles Times, CA - 10 hours ago A Harvard graduate who works at the Maryland Digestive Disease Center, Shih was one of 41 pianists, 35 and older, from Italy, Japan, Mexico, Romania and the ...

How to look hot in the cold - Courier Mail

How to look hot in the cold Courier Mail, Australia - 1 hour ago a These will include ingredients such as silicones, which protect the skina s barrier; panthenol; vitamins A, C and E, which repair and heal the skin; ...

Welcare marks World No Tobacco Day with free 'Quit Smokinga clinic - AME Info

Welcare marks World No Tobacco Day with free 'Quit Smokinga clinic AME Info, United Arab Emirates - 1 hour ago Exposure to second-hand smoke causes heart disease and many serious respiratory and cardiovascular diseases that can lead to premature death in adults. ...

Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for ... - FOXBusiness

Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for ... FOXBusiness - 20 hours ago ... more accurate molecular diagnostic tests to detect life-threatening infectious diseases such as cervical cancer," said Carl Hull, Gen-Probe's president ...

Sunday's AIDS Walk Boston at the Esplanade Gets Tribute from Cyndi Lauper at True Colors Concert Tour Launch Rehearsal Public Invited for Sunday's AIDS Walk, Run and Wellness Festival with Festivities at 9:30 a.m., Walk at 10 a.m.

BOSTON, May 31 /PRNewswire-USNewswire/ -- Cyndi Lauper, in Boston to launch the True Colors Tour this weekend, took a break from her rehearsal on Friday night to meet with some of this year's top fundraisers for Sunday's 23rd Annual AIDS Walk Boston.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080531/CLSA004 )

The 23rd Annual AIDS Walk Boston and the Larry Kessler 5K Run event is on Sunday, June 1st with opening ceremonies at 9:30 a.m., and the Walk starts at 10 a.m. Concurrent with and following the Walk and Run is the Wellness Festival. The public is invited to participate in all aspects of the day's festivities on the Esplanade, and to cheer Walkers along as they fight HIV/AIDS, which still in Massachusetts claims 2-3 new infections every day.

Since AIDS Walk Boston began in 1986, more than 200,000 people have participated and raised more than 0 million for the programs and services of AIDS Action Committee of Massachusetts (AAC). In 2007, AIDS Walk Boston had more than 15,000 participants, including a record 453 teams, and raised .2 million for AAC.

The True Colors Tour, including The B-52's, Rosie O'Donnell, The Clicks and hosted by infamous "Queer Eye Guy" Carson Kressley, kicks off its 24-city run on Saturday in Boston at the Bank of Boston Pavilion at 6 p.m. and moves Sunday to The Jones Beach Theater on Long Island and then to Radio City Music Hall on Tuesday.

AIDS Walk Boston website: http://www.aidswalkboston.org/ True Colors Tour website: http://www.truecolorstour.com/

Editor's Note -- AIDS Walk Boston: Interviews with people about why they walk, who they honor in tribute and stories of remembrance and hope are available and can be scheduled or granted on-site. Photo and video opportunities can be planned or granted on-site.

Contact: Diego Sanchez, dsanchez@aac.org, 617.835.1455, 617.450.1524 or

Paul Twitchell, ptwitchell@aac.org, 617.450.1215

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080531/CLSA004
AP Archive: http://photoarchive.ap.org/
AP PhotoExpress Network: PRN1
PRN Photo Desk, photodesk@prnewswire.com AIDS Action Committee of Massachusetts

CONTACT: Diego Sanchez, dsanchez@aac.org, 1-617-835-1455, or
1-617-450-1524, Paul Twitchell, ptwitchell@aac.org, 1-617-450-1215, both of
AIDS Action Committee of Massachusetts

Web Site: http://www.aac.org/
http://www.aidswalkboston.org/
http://www.truecolorstour.com/

AMSTERDAM (Thomson Financial) - AMSTERDAM (Thomson Financial ... - Forbes

AMSTERDAM (Thomson Financial) - AMSTERDAM (Thomson Financial ... Forbes, NY - 13 hours ago -Fortis (other-otc: FORSY.PK - news - people ) advanced 0.32 percent to 15.73 after JP Morgan initiated the stock at 'underweight'. ...

Syndexa socks away 5M from Hittite Microwave founder, others - Bizjournals.com

Syndexa socks away 5M from Hittite Microwave founder, others Bizjournals.com, NC - 11 hours ago Its drugs are intended to target novel metabolic functions in the body to prevent obesity, type 2 diabetes and cardiovascular disease. ...

FDA Panel Backs Glaxo Platelet Drug Promacta - Wall Street Journal

FDA Panel Backs Glaxo Platelet Drug Promacta Wall Street Journal - 6 hours ago Even though the proposed use of the drug is for short-term use, it's likely that once it gets on the market people would use it longer term since ITP is a ... PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ... Earthtimes (press release) all 116 news articles

UWI to expand Clinical Trials Centre - Jamaica Observer

UWI to expand Clinical Trials Centre Jamaica Observer, Jamaica - 20 minutes ago THE University of the West Indies (UWI) is getting ready to expand its Clinical Trials Centre as it prepares to embark on its 10th clinical trial since it ...

An Expert Interview With Giancarlo Comi, MD - Medscape (subscription)

An Expert Interview With Giancarlo Comi, MD Medscape (subscription) - 1 hour ago The drug entered the market in 1993 in the United States and a couple of years later in Europe. There were 3 parallel treatment arms in the BEYOND trial, ...

China yuan ends at 6.9420 to US dollar vs 6.9381 in OTC trade - Forbes

China yuan ends at 6.9420 to US dollar vs 6.9381 in OTC trade Forbes, NY - 16 hours ago The yuan traded between 6.9410 and 6.9459 on the OTC market and between 6.9415 and 6.9434 on the exchange-traded market. The central bank set the yuan ...

Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex Isolagen Intends to Appeal Action

EXTON, Pa., May 30 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. today announced that on May 29, 2008 it received notice from the staff of the American Stock Exchange (AMEX) indicating that, in the staff's opinion, the Company's plan of compliance did not demonstrate its ability to regain compliance with the Exchange's continued listing standards set forth in Sections 1003 (a)(i)-(iii) of the AMEX Company Guide within the prescribed time period, and, therefore, that its common stock is subject to being delisted from the Exchange. As discussed in the Company's Form 8-K dated March 14, 2008 and in Item 1A. of the Company's Form 10-Q for the quarter ended March 31, 2008, the Company had initially received a non-compliance notice from the staff of the AMEX on March 12, 2008, and had submitted a plan of compliance to the AMEX on April 14, 2008.

Isolagen intends to appeal this determination and will request a hearing before a committee of the Exchange. There can be no assurance that the Company's request for continued listing will be granted after such hearing.

About Isolagen, Inc.

Isolagen(TM), Inc. is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com/.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release, include, without limitation, that the Company's request for continued listing with AMEX will be granted. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward- looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date

Isolagen, Inc.

CONTACT: Mike Beyer of Sam Brown, Inc., 1-773-463-4211,
beyer@sambrown.com, for Isolagen, Inc.

Web site: http://www.isolagen.com/

EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435

DURHAM, N.C., May 30 /PRNewswire/ -- Dr. George C. Clark of Xenobiotic Detection Systems (XDS) and Dr. Michael Denison at the University of California Davis, with support from the Superfund Basic Research Program, have developed a rapid and inexpensive recombinant cell bioassay system for the detection and relative quantification of dioxin-like chemicals. Dioxin-like chemicals are some of the most toxic chemicals known.

The CALUX(R) by XDS (Chemical Activated LUciferase Gene Expression) system has recently been published and is posted under "New Methods" on the SW-846 website. In March 2008, the EPA's Office of Solid Waste (OSW) Organic Methods Workgroup formally reviewed and approved Method 4435 for inclusion into Test Methods for Evaluating Solid Waste, Physical/Chemical Methods, also known as SW-846. The XDS-CALUX system consists of a unique sample processing method linked with a sensitive gene expression cell bioassay detection system providing unique sensitivity and selectivity for quantifying dioxin-like chemicals.

The XDS-CALUX(R) bioassay costs are 40%-70% lower than the traditional High Resolution Gas Chromatography/Mass Spectrometry (HR GC/MS) that was the old singular analysis standard. Xenobiotic Detection Systems Method 4435 provides an excellent screening tool to rapidly detect and quantify these ubiquitous and toxic environmental contaminants.

"This approval exemplifies the assay's versatility and is another major step for XDS," says President of XDS, Dr. George Clark. "Having been certified in the European Union since 2002 to primarily monitor feed and food it is wonderful to receive accreditation here in the U.S. Our screening analysis method is faster, far more affordable, and in many cases even more sensitive than the traditional HR GC/MS. The EPA's approval will allow us to better serve our clients and safeguard the environment from these toxic contaminants."

Research Institutes Worldwide using XDS-CALUX(R) Technology includes the United States: US FDA and University of California Davis. Asia: Hiyoshi Corporation of Japan, Cheng-Shiu University, Taiwan. Europe: Scientific Institute of Public Health, Brussels, Belgium, Federal Feed Laboratory, Tervuren, Belgium, and the National Veterinary Research Institute, Pulawy, Poland.

Development of the XDS-CALUX(R) technology was funded in part by Superfund Basic Research Program Grant (ES04699), and by Small Business Innovation Research Grants from the National Institute of Environmental Health Sciences (ES 08372-01 and ES 08372-02).

Additional information: XDS (http://www.dioxins.com/) or call 1-888-D-I-O-X-I-N-S

(R) "Registered US Trademark and Patent Office"

Xenobiotic Detection Systems

CONTACT: Rob Clark, XDS, 1-919-688-4804 or 1-888-DIOXINS,
RobClark@dioxins.com

Web site: http://www.dioxins.com/

France: A leader in clinical trials - Merinews

France: A leader in clinical trials Merinews, India - 14 hours ago Clinical trials are a vital element of the pharmaceutical industry, in which France is considered the best in Europe. Its expertise is derived from several ...

Rotigotine Skin Patch May Ease Restless Legs Symptoms - Forbes

Rotigotine Skin Patch May Ease Restless Legs Symptoms Forbes, NY - 35 minutes ago The study was published online in The Lancet Neurology and was expected to be in the July print issue of the journal. "The introduction of a patch with a ...

Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence

CHAPEL HILL, N.C., May 30 /PRNewswire/ -- Given the increasing challenges to patent protection and new product approvals, pharmaceutical companies continue to seek external opportunities to grow their pipelines. With the increasing merger and acquisition activity, industry experts have found the importance of proper integration of assets to be key in obtaining value as described in the newly published study, "M&A Integration Excellence: What Bio- Pharma Companies Need to Know." Best Practices, LLC recently completed this new study utilizing benchmark metrics and executive insights to assess current trends and future directions of bio-pharmaceutical M&A activity and keys to obtaining asset value through optimal integration.

In a benchmarking study that included such influential companies as Pfizer, Lilly, Johnson & Johnson and Abbott, it was found that managing cultural issues was both highly important and extremely difficult to optimize. Integration experts discussed methods for managing such issues through proper planning and execution as described in the study report.

For a complimentary summary of the full report "M&A Integration Excellence: What Bio-Pharma Companies Need to Know," click on the following link http://www3.best-in-class.com/rr952.htm.

Other key topic areas in the research include: - Structure for Integration - Pre-Integration Planning Activities - Integration Risk Management - Integration Functional Excellence - Communications Excellence - Understanding & Managing Cultural Issues - Post-Deal Closure Integration Activities - Trends in M&A Integration Among the key topics gathered in this report are: - Industry Integration Functional Efficacy - Efficacy of Integration Structural Approaches - Integration Planning Initiation - Pre-Integration Planning Activity Efficacy - Integration Planning Activity Resource Intensity - Integration Risk-Assessment Factor Importance - Integration Approach Assessments - Post-Deal Closure Integration Ownership - Time to Integration Stability By Organization Size - Performance Indicators for Integration Performance Measurement

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr952.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.

Best Practices, LLC

CONTACT: Kim Hardin, Best Practices, LLC, 1-919-767-9221,
khardin@best-in-class.com

Web site: http://www.best-in-class.com/
http://www3.best-in-class.com/rr952.htm

Merck to Seek Appellate Review of Class Certification Decision in ... - Canada NewsWire (press release)

Merck to Seek Appellate Review of Class Certification Decision in ... Canada NewsWire (press release), Canada - 1 hour ago ... has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes and osteoporosis. ...

Single pill for all lifestyle ailments - Times of India

Single pill for all lifestyle ailments Times of India, India - 23 hours ago Cardiovascular diseases are the world's leading killer, accounting for over 17 million or 30% of total global deaths. In India, over 10 crore people are ...

Lupin Receives USFDA Approval for Topiramate Tablets

BALTIMORE, May 30 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Topiramate tablets, 25 mg, 50 mg, 100 mg and 200 mg from the U.S. Food and Drug Administration (USFDA).

Lupin's Topiramate tablets are the AB-rated generic equivalent of Ortho-McNeil's TOPAMAX(R) tablets, indicated for the treatment of seizures. The brand product had annual sales of approximately .2 billion for the twelve months ended March 2008, based on IMS Health sales data.

Commenting on the approval, Vinita Gupta, President and Managing Director of Lupin Pharmaceuticals, Inc. said, "Lupin is pleased to receive this approval that will enable the Company to offer Topiramate tablets as an affordable generic alternative that will have a measurable impact on the U.S. healthcare system."

The product will be introduced in the market through LPI's strong network of national wholesalers and drug stores post patent expiry in September 2008. This will strengthen Lupin's presence in the CNS segment.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs.

The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into New Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US$ 694 million) and Rs.4,083 million (US$ 102 million) respectively. Please visit http://www.lupinworld.com/ for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top six Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com/.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

TOPAMAX(R) is a registered trademark of Ortho-McNeil Neurologics, Inc. Contact: Edith St-Hilaire Senior Marketing Manager 410-576-2000 Ext. 207

Lupin Pharmaceuticals, Inc.

CONTACT: Edith St-Hilaire, Senior Marketing Manager of Lupin
Pharmaceuticals, Inc., 1-410-576-2000, ext. 207

Web site: http://www.lupinpharmaceuticals.com/

About 60 Clinical Studies Regarding Schering-Plough's Oncology ... - Earthtimes (press release)

About 60 Clinical Studies Regarding Schering-Plough's Oncology ... Earthtimes (press release), UK - 2 hours ago ... Securities Litigation Reform Act of 1995, including statements relating to the potential market and the clinical development of its oncology portfolio. ...

Pay Attention to These Stocks - Motley Fool

Pay Attention to These Stocks Motley Fool - 1 hour ago Pink Sheets Chairman and CEO R. Cromwell Coulson told me he's trying to "change the OTC market from fraud risk to investment risk. ...

Delisting Notification Received from the American Stock Exchange Company to evaluate appeal options

TORONTO, May 30 /PRNewswire-FirstCall/ -- Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today announced it has been notified by the American Stock Exchange (the "AMEX") that it will not continue to support PreMD's plan for regaining compliance with the continued listing standards and that it intends to delist the Company's common stock from the Exchange by filing a delisting application with the Securities and Exchange Commission (the "SEC") pursuant to Section 1009(d) of the AMEX Company Guide (the "Company Guide"). The determination by the staff of the AMEX to initiate the delisting of the common stock from the AMEX is based on the Company's failure to meet several of the Exchange's conditions for continued listing.

Presently, the Company continues to be noncompliant with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the Company Guide, all of which relate to the Company's insufficient stockholder's equity as previously reported in the Company's filings with the SEC. The AMEX also cites deficiencies regarding the Company's ongoing losses and low share price as additional reasons for the staff's determination. The Company is currently evaluating its options in dealing with the AMEX and will provide updates as they become available. It is management's view that PreMD's delisting on the AMEX does not affect its current listing on the Toronto Stock Exchange (the "TSX").

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include a line of non-invasive skin cholesterol tests. PreMD's other skin cholesterol products include PREVU(x) LT, a skin cholesterol test designed for use in the life insurance industry. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com/.

PreMD Inc.

CONTACT: Ron Hosking, Vice-President, Finance, Tel: (416) 222-3449,
Email: rhosking@premdinc.com; Michelle Rabba, Manager, Corporate
Communications, Tel: (416) 222-3449 ext. 25, Email: mrabba@premdinc.com